Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434895 | 0.88 | TET2 (0.53) | EGLN1ALDH1A1LMNAGAATET2 | |
| SCHEMBL1337998 | 0.83 | EGLN1 (0.58) | EGLN1ALDH1A1GAATET2TDP1 | |
| SCHEMBL8220165 | 0.80 | GAA (0.47) | ALDH1A1LMNAGAAACHE | |
| SCHEMBL5854855 | 0.79 | EGLN1 (0.70) | EGLN1ALDH1A1GAATET2POLB | |
| SCHEMBL26247715 | 0.76 | ALDH1A1 (0.50) | ALDH1A1LMNATDP1POLBFAAH | |
| SCHEMBL21986654 | 0.76 | NAAA (0.59) | ALDH1A1LMNAFAAHLPAR2LPAR3 | |
| Hydrochloric Acid SCHEMBL6031053 | 0.75 | EGLN1 (0.49) | EGLN1ALDH1A1LMNAGAATET2 | |
| SCHEMBL434612 | 0.75 | CA12 (0.43) | ALDH1A1LMNAGAATDP1POLB | |
| SCHEMBL26247997 | 0.74 | ALDH1A1 (0.53) | ALDH1A1LMNAFAAHLPAR2LPAR3 | |
| SCHEMBL873655 | 0.74 | NAAA (0.62) | ALDH1A1LMNAFAAHLPAR2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595994-B1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2595994-B1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| EP-2595994-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | Glaxo Group Limited (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2012012391-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012391-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | DHPS, AKR1C3, Q6ZSR9 | EGLN1 825/4885ALDH1A1 186/4885LMNA 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.